16 April 2026, New Delhi
ICAR–National Research Centre on Equines, Hisar, Haryana in collaboration with ICAR–Indian Veterinary Research Institute, Bareilly has successfully developed an indigenous, homologous live-attenuated vaccine for Lumpy Skin Disease (LSD) to effectively combat the disease in cattle across the country. The vaccine has been demonstrated to be safe for cattle of all age groups, and is known to elicit a strong and robust cell-mediated immune response.
The technology was transferred to M/s Brilliant Bio Pharma Pvt. Ltd., Hyderabad, Telangana today. The Technology License Agreement was formally signed in New Delhi, in the august presence of Dr M.L. Jat, Secretary, DARE & Director General, ICAR.
On this occasion Dr Raghavendra Bhatta, Deputy Director General (Animal Science) and Director, ICAR-IVRI; Dr T. K. Bhattacharya, Director, ICAR-NRCE, Hisar; Dr Praveen Malik, Chief Executive Officer, Agrinnovate India Ltd; along with Mr. Biswanath Mishra, Sr. Vice President, M/s Brilliant Bio Pharma Pvt. Ltd., Hyderabad, Telangana and other distinguished officials were present.
With this transfer, M/s Brilliant Bio Pharma Pvt. Ltd. becomes the sixth firm to receive the LSD vaccine technology. The agreement includes a technology licensing fee of ₹75.00 lakh plus GST, along with a royalty of 5% on sales, paving the way for large-scale production and wider dissemination of the vaccine for effective disease control in the livestock sector.
(Source: Division of Animal Sciences, ICAR)
Like on Facebook
Subscribe on Youtube
Follow on X X
Like on instagram